Statin/Ezetimbe Combination Therapy: Emerging Evidence

More documents

Recommendations

Info

What is New about Simvastatin/ Ezetimibe <strong>Combination</strong> ?
SHARP: Rationale • Risk of vascular events is high among patients with chronic kidney disease • Lack of clear association between cholesterol level and vascular disease risk in CKD • Pattern of vascular disease is atypical, with a large proportion being non-atherosclerotic • Previous trials of LDL-lowering therapy in chronic kidney disease are inconclusive
Page 1 and 2: Statin/Ezetimbe Combination Therapy
Page 3 and 4: Recommendations for Lipid Analyses
Page 5 and 6: Cholesterol Goal Attainment in Egyp
Page 7 and 8: Cholesterol Goal Attainment in Egyp
Page 9 and 10: Why do statins alone don’t get ou
Page 11 and 12: Statins Adverse Events • Hepatoto
Page 13 and 14: Severe Adverse Event Rates for Each
Page 15 and 16: INHIBITION OF CHOLESTEROL SYNTHESIS
Page 17 and 18: Exogenous Endogenous Cholesterol Ab
Page 19 and 20: CAI THE INHIBITION OF CHOLESTEROL A
Page 21 and 22: Switching to Combination vs. Statin
Page 23 and 24: EfficACy and SafeTy of Ezetimibe Ad
Page 25 and 26: EfficACy and SafeTy of Ezetimibe Ad
Page 27 and 28: The Vytorin on CIMT and Overall Art
Page 29 and 30: A Recent Meta-analysis May 2011 27
Page 31: LDL-C Goal Achievement 100 90 80 70
Page 35 and 36: Study of Heart And Renal Protection
Page 37 and 38: Proportion suffering event (%) SHAR
Page 39 and 40: Proportion suffering event (%) SHAR
Page 41 and 42: First ESC/EAS guidelines for dyslip
Page 43: Overall Conclusion • A beneficial

Statin/Ezetimbe Combination Therapy: Emerging Evidence

Create successful ePaper yourself

Delete template?

Save as template?